Latest News in the pharma Industry

Research & Development

Janssen's two-drug combination demonstrates efficacy in maintaining viral suppression

Janssen's two-drug combination demonstrates efficacy in maintaining viral suppression

14 Feb 2017

If approved, this treatment could be the first two-drug regimen for HIV.

Read more 
Ferring backs Foresee's SIF platform for controlled-release formulations

Ferring backs Foresee's SIF platform for controlled-release formulations

13 Feb 2017

Foresee technology can help to develop stable, formulated peptides in solution for controlled-release therapy for 3- and 6-month durations of action after a single injection.

Read more 
Aquarium-to-bedside drug shows promise in small pediatric trial

Aquarium-to-bedside drug shows promise in small pediatric trial

12 Feb 2017

NIH-funded research suggests zebrafish models may be efficient resource for identifying drugs for clinical use.

Read more 
First patient enrolled in Phase II study evaluating JZP-110 for excessive sleepiness in Parkinson's disease

First patient enrolled in Phase II study evaluating JZP-110 for excessive sleepiness in Parkinson's disease

12 Feb 2017

JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor.

Read more 
Afatinib to be evaluated in combination with pembrolizumab in new trial for patients with SqCC of the lung

Afatinib to be evaluated in combination with pembrolizumab in new trial for patients with SqCC of the lung

9 Feb 2017

Boehringer Ingelheim to conduct trial in collaboration with a subsidiary of Merck (MSD).

Read more 
Designer compound may untangle damage leading to some dementias

Designer compound may untangle damage leading to some dementias

9 Feb 2017

NIH-funded preclinical study suggests a possible treatment for Alzheimer’s disease and other neurodegenerative disorders.

Read more 
STA Pharma expands R&D team at is Changzhou site

STA Pharma expands R&D team at is Changzhou site

6 Feb 2017

By the end of 2017, company plans to increase to 230 process chemists and 70 analytical chemists.

Read more 
Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study

Amgen's Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study

6 Feb 2017

Landmark Repatha cardiovascular outcomes study meets primary and key secondary endpoint.

Read more 
FDA accepts two sBLAs for Merck's Keytruda for metastatic urothelial cancer

FDA accepts two sBLAs for Merck's Keytruda for metastatic urothelial cancer

5 Feb 2017

Keytruda also receives Breakthrough Therapy Designation for second-line treatment.

Read more 
FDA approves BMS's Opdivo for bladder cancer

FDA approves BMS's Opdivo for bladder cancer

5 Feb 2017

Opdivo has now been approved in six tumour types in just over 2 years.

Read more 
Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC

Merck gets the thumbs up in Europe for Keytruda to treat patients with metastatic NSCLC

2 Feb 2017

First anti-PD-1 therapy approved in Europe for previously untreated patients with metastatic NSCLC.

Read more 
Novartis' Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC

Novartis' Votubia receives EU approval to treat refractory partial-onset seizures in patients with TSC

31 Jan 2017

Decision marks the third TSC-related indication for Votubia in the EU.

Read more